R. Hector MacKay-Dunn
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About R. Hector MacKay-Dunn
Aurinia Pharmaceuticals Inc. reported in an 8-K filed September 12, 2024 that R. Hector MacKay-Dunn resigned as Director. Aurinia Pharmaceuticals Inc. reported in an 8-K filed September 12, 2024 that R. Hector MacKay-Dunn resigned as director, effective September 9, 2024.
“The Board has accepted the conditional resignations of Daniel G. Billen, Ph.D., R. Hector MacKay-Dunn, J.D., and Brinda Balakrishnan, M.D., Ph.D., who received less than majority support at the Meeting.”
“the Board, following the deliberation process outlined in the Company's Majority Voting Policy, determined (i) to accept the resignations of Dr. Billen, Mr. MacKay-Dunn, and Dr. Balakrishnan, effective September 9, 2024”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Aurinia Pharmaceuticals Inc. (AUPH)
Proxy statement
Start not stated–2024-05-03
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.